222 related articles for article (PubMed ID: 37907944)
1. Conventional type 1 dendritic cells (cDC1) in cancer immunity.
Liu P; Zhao L; Kroemer G; Kepp O
Biol Direct; 2023 Nov; 18(1):71. PubMed ID: 37907944
[TBL] [Abstract][Full Text] [Related]
2. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G
Front Immunol; 2020; 11():631713. PubMed ID: 33679726
[TBL] [Abstract][Full Text] [Related]
4. A distinct stimulatory cDC1 subpopulation amplifies CD8
Meiser P; Knolle MA; Hirschberger A; de Almeida GP; Bayerl F; Lacher S; Pedde AM; Flommersfeld S; Hönninger J; Stark L; Stögbauer F; Anton M; Wirth M; Wohlleber D; Steiger K; Buchholz VR; Wollenberg B; Zielinski CE; Braren R; Rueckert D; Knolle PA; Kaissis G; Böttcher JP
Cancer Cell; 2023 Aug; 41(8):1498-1515.e10. PubMed ID: 37451271
[TBL] [Abstract][Full Text] [Related]
5. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
6. Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.
He F; Wu Z; Liu C; Zhu Y; Zhou Y; Tian E; Rosin-Arbesfeld R; Yang D; Wang MW; Zhu D
Signal Transduct Target Ther; 2024 May; 9(1):139. PubMed ID: 38811552
[TBL] [Abstract][Full Text] [Related]
7. Conventional Type 1 Dendritic Cells in Intestinal Immune Homeostasis.
Sasaki I; Kato T; Hemmi H; Fukuda-Ohta Y; Wakaki-Nishiyama N; Yamamoto A; Kaisho T
Front Immunol; 2022; 13():857954. PubMed ID: 35693801
[TBL] [Abstract][Full Text] [Related]
8. The role of dendritic cells in cancer.
Lee YS; Radford KJ
Int Rev Cell Mol Biol; 2019; 348():123-178. PubMed ID: 31810552
[TBL] [Abstract][Full Text] [Related]
9. The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity.
Böttcher JP; Reis e Sousa C
Trends Cancer; 2018 Nov; 4(11):784-792. PubMed ID: 30352680
[TBL] [Abstract][Full Text] [Related]
10. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cells.
Lau CM; Tiniakou I; Perez OA; Kirkling ME; Yap GS; Hock H; Reizis B
J Exp Med; 2018 Sep; 215(9):2265-2278. PubMed ID: 30087163
[TBL] [Abstract][Full Text] [Related]
12. Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities.
Johnson P; Rosendahl N; Radford KJ
Expert Opin Biol Ther; 2022 Apr; 22(4):465-472. PubMed ID: 34654337
[TBL] [Abstract][Full Text] [Related]
13. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy.
Teijeira A; Garasa S; Luri-Rey C; de Andrea C; Gato M; Molina C; Kaisho T; Cirella A; Azpilikueta A; Wculek SK; Egea J; Olivera I; Rodriguez I; Rouzaut A; Verkhusha V; Valencia K; Sancho D; Berraondo P; Melero I
Cancer Res; 2022 Dec; 82(23):4373-4385. PubMed ID: 36130020
[TBL] [Abstract][Full Text] [Related]
14. CD4
Lei X; Khatri I; de Wit T; de Rink I; Nieuwland M; Kerkhoven R; van Eenennaam H; Sun C; Garg AD; Borst J; Xiao Y
Nat Commun; 2023 Jan; 14(1):217. PubMed ID: 36639382
[TBL] [Abstract][Full Text] [Related]
15. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity.
Liang Y; Hannan R; Fu YX
Clin Cancer Res; 2021 Jul; 27(14):3818-3824. PubMed ID: 33692027
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.
Lahoud MH; Radford KJ
Hum Vaccin Immunother; 2022 Dec; 18(1):1873056. PubMed ID: 33625943
[TBL] [Abstract][Full Text] [Related]
17. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
[TBL] [Abstract][Full Text] [Related]
18. DNGR-1-mediated cross-presentation of dead cell-associated antigens.
Henry CM; Castellanos CA; Reis e Sousa C
Semin Immunol; 2023 Mar; 66():101726. PubMed ID: 36758378
[TBL] [Abstract][Full Text] [Related]
19. Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells.
Rosa FF; Pires CF; Kurochkin I; Halitzki E; Zahan T; Arh N; Zimmermannová O; Ferreira AG; Li H; Karlsson S; Scheding S; Pereira CF
Sci Immunol; 2022 Mar; 7(69):eabg5539. PubMed ID: 35245086
[TBL] [Abstract][Full Text] [Related]
20. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses.
Bayerl F; Meiser P; Donakonda S; Hirschberger A; Lacher SB; Pedde AM; Hermann CD; Elewaut A; Knolle M; Ramsauer L; Rudolph TJ; Grassmann S; Öllinger R; Kirchhammer N; Trefny M; Anton M; Wohlleber D; Höchst B; Zaremba A; Krüger A; Rad R; Obenauf AC; Schadendorf D; Zippelius A; Buchholz VR; Schraml BU; Böttcher JP
Immunity; 2023 Jun; 56(6):1341-1358.e11. PubMed ID: 37315536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
